Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case‐control study

@article{Johannes2010RiskOS,
  title={Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case‐control study},
  author={Catherine B. Johannes and Cristina Varas‐Lorenzo and Lisa J. McQuay and Kirk D. Midkiff and Daniel Fife},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2010},
  volume={19}
}
Limited information from spontaneous reports and results of two case‐control studies raised concern about the cardiotoxicity of oral domperidone therapy. This case‐control study nested in a retrospective cohort evaluated the combined risk of serious ventricular arrhythmia (SVA) and sudden cardiac death (SCD) in users of domperidone compared with users of proton pump inhibitors (PPIs), or non‐users of these medications. 
Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies
TLDR
Domperidone is associated with an increased risk of sudden cardiac death and ventricular arrhythmia compared to non-use and this association persisted when restricted to higher-quality studies when data were pooled across non-overlapping studies. Expand
Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study
TLDR
Compared with non-use of any study drug, current domperidone use was associated with sudden cardiac death in nested case-control and case-crossover analyses, with a suggestion of higher risk in older persons and users of higher daily doses. Expand
Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease
TLDR
Domperidone use may increase the risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) in patients with PD, particularly those with a history of cardiovascular disease. Expand
Media attention regarding sudden cardiac death associated with domperidone use does not affect in hospital ECG recording
TLDR
The aim of the study was to assess the effect of regulatory warnings and the resulting media hype on the frequency of electrocardiogram (ECG) monitoring of inpatients using domperidone. Expand
Increased risk of all‐cause mortality associated with domperidone use in Parkinson's patients: a population‐based cohort study in the UK
TLDR
This work sought to examine the risk of all‐cause mortality associated with domperidone exposure in PD and found that exposure to the drug is linked to an increased risk of mortality. Expand
Risk of Serious Ventricular Arrhythmia in Users of Gastrointestinal Medications: A Retrospective Cohort Study in China
TLDR
SVA and cardiac arrest are very rare events in patients prescribed medications for gastrointestinal disorders in China and there is no evidence that domperidone carried a higher risk of SVA compared to other gastrointestinal medications. Expand
[Cardiac adverse effects of domperidone in adult patients: a systematic review].
TLDR
Evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults and a significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Expand
Risk of domperidone induced severe ventricular arrhythmia
TLDR
Domperidone, mosapride, or itopride use is associated with an increased risk of severe VA, however, the magnitude of association was modest and dom peridone use does not increase further the risk, compared with other prokinetics. Expand
Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case–crossover study
TLDR
The aim of this study was to investigate the association between oral domperidone, CYP 3A4 inhibitors, and ventricular arrhythmia. Expand
Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review.
TLDR
Given gaps in the literature, use of domperidone for patients undergoing dialysis should be assessed on a case-by-case basis and extreme caution should be used for patients taking more than 30 mg/day of this drug. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.
TLDR
The use of non-cardiac QTc-prolonging drugs in a general population is associated with an increased risk of sudden cardiac death. Expand
Antipsychotics and the risk of sudden cardiac death.
TLDR
Current use of antipsychotics in a general population is associated with an increased risk of sudden cardiac death, even at a low dose and for indications other than schizophrenia. Expand
Atypical antipsychotic drugs and the risk of sudden cardiac death.
TLDR
Current users of typical and of atypical antipsychotic drugs had a similar, dose-related increased risk of sudden cardiac death. Expand
In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.
TLDR
Use of non-antiarrhythmic QTc-prolonging drugs in hospitalized patients with several underlying disease is associated with an increased risk of cardiac arrest, and the effect is dose related and pharmacokinetic drug-drug interactions increase the risk substantially. Expand
Oral erythromycin and the risk of sudden death from cardiac causes
TLDR
The association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A was studied. Expand
Cardiac Arrhythmias during Cytotoxic Chemotherapy: Role of Domperidone
TLDR
Treatment with intravenous domperidone is associated with the occurrence of cardiac arrhythmias in patients receiving platinum-containing chemotherapy and a control group of 14 patients treated with similar chemotherapy also underwent cardiac and plasma potassium monitoring. Expand
QT Interval Prolongation Associated with the Oral Use of Domperidone in an Infant
TLDR
A 4-month-old child who presented with QT interval prolongation after the oral use of domperidone, which normalized after the drug was discontinued, is reported. Expand
Antibiotics; adverse effects: Oral erythromycin and the risk of sudden death from cardiac causes
Certain concurrent medications increase plasma erythromycin concentration, sometimes causing tachycardia, ventricular arrhythmias and death.
SUDDEN DEATH IN CANCER PATIENT ON HIGH-DOSE DOMPERIDONE
TLDR
The antiemetic effect was disappointing, but no sideeffects were observed, so the dosage of domperidone was increased, and at the eleventh dose escalation one patient died and death may have been related to dom peridone. Expand
Making a case for domperidone in the treatment of gastrointestinal motility disorders.
TLDR
There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis, and medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Expand
...
1
2
3
...